Thermo Fisher Scientific Apolipoprotein B Monoclonal Antibody (F2C9)

Applications

Tested Dilution

Publications

Western Blot (WB)

2 µg/mL

View 1 publication 1 publication

Immunocytochemistry (ICC/IF)

2-4 µg/mL

-

ELISA (ELISA)

Assay-dependent

-

Immunoprecipitation (IP)

Assay-dependent

-

Radioimmune Assays (RIA)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

F2C9

Immunogen

Purified human serum LDL if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:Apolipoprotein B,uniProtId:P04114-1,ncbiNodeId:9606,antigenRange:1-4563,antigenLength:4563,antigenImageFileName:MIA1609_Apolipoprotein_B_P04114-1_House_mouse.svg,antigenImageFileNamePDP:MIA1609_Apolipoprotein_B_P04114-1_House_mouse_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

5 mg/mL

Purification

Protein A

Storage buffer

PBS, pH 7.4

Contains

0.09% sodium azide

Storage conditions

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_11152638

Product Specific Information

MIA1609 targets Apolipoprotein B in ELISA, IP and RIA applications and shows reactivity with Human samples.

The MIA1609 immunogen is purified human serum LDL.

MIA1609 detects Apolipoprotein B which has a predicted molecular weight of approximately 502 kDa.

MIA1609 was formerly sold as a Seradyn product.

Target Information

Apolipoprotein B (apo B) in human plasma is a major protein of low density lipoproteins (LDL) with a molecular mass of approximately 260-500 kDa. Apolipoprotein B binds to specific receptors on cell membranes and is involved in removal of LDL and very low density lipoprotein (VLDL) cholesterol from circulation. Low-density lipoprotein (LDL) is the carrier protein for cholesterol in the blood. LDL binds to its receptor on the capillary walls and thereby mediates the uptake and clearance of cholesterol from the circulation. In atherosclerotic lesions oxidatively modified LDL is found and oxidized LDL is specifically recognized and ingested by macrophages via scavenger receptor A and CD36. Oxidized LDL may be a marker of atherosclerosis but the precise changes in oxidized LDL are not well described. MDA-oxidized LDL appear to be different from LDL oxidized by other means. Apolipoprotein B is mostly synthesized in the liver, and is a major apolipoprotein of very low density, intermediate density and low density lipoproteins (LDL) as well as being a major component of lipoprotein (a). Apolipoprotein B is a ligand for the LDL receptor and elevated levels are associated with premature atherosclerosis. Normal plasma apolipoprotein B levels are around 800mg/L. Apolipoprotein B occurs in plasma as two main isoforms, apoB-48 and apoB-100. The intestinal and the hepatic forms of Apolipoprotein B are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in the Apolipoprotein B gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective Apolipoprotein B, diseases affecting plasma cholesterol and Apolipoprotein B levels.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.